Cardiovascular Disease
At a glance...
Acute coronary syndromes—pathogenesis, endothelial injury, platelets and coagulation, preclinical canine studies, platelet GPIIb/IIIa inhibitors, thrombin inhibitors, fibrinolytics, percutaneous coronary interventions, stents
Hypertension—ACE inhibitors, angiotensin receptor blockers, beta-blockers, renin inhibitors, the elderly, chronotherapy, managed care issues, ambulatory BP monitoring, guidelines, adherence issues Dyslipidemia—lipid-lowering strategies, diabetes, insulin resistance, statins |
Acute Coronary Syndromes "A nitinol stent or Wallstent for suboptimal iliac angioplasty: CRISP-US trial results” (clinical trial) “Breaking the thrombolytic barrier: combining glycoprotein IIb/IIIa receptor inhibitors with thrombolytic therapy in the treatment of acute myocardial infarction” (review) "The medical management of acute coronary syndromes and potential roles for new antithrombotic agents” (review) "Acute coronary syndromes and percutaneous interventions: integrated pathophysiology and management strategies” (review) "Modulation of endothelial injury and prevention of ischemia” (review) "Platelets, coagulation, and the thrombotic process” (review) "Platelet glycoprotein IIb/IIIa inhibitors: the final common pathway of platelet aggregation” (review) "Inhibition of platelet aggregation by orbofiban, an orally active GP IIb/IIIa platelet antagonist, in dogs following repeated dosing” (preclinical) "Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist” (preclinical) "Effects of the active metabolite of orbofiban on prevention of coronary artery thrombosis in dogs” (preclinical) "Efficacy of orally administered orbofiban and its interaction with aspirin or heparin in a canine model of coronary electrical injury” (preclinical) "Antithrombotic activity of xemilofiban in a canine model of cyclic flow reductions” (preclinical) Hypertension "Outcomes in Cardiovascular Disease: Hypertension and Its Sequelae" (CME Monograph) "Endothelial dysfunction: linking hypertension to systemic and local disease” (review) "Hypertension in the older patient” (managed care supplement article) "The HOT study: implications for hypertension management and the J-shape curve” (managed care supplement article) "Barriers to guideline adherence” (managed care supplement article) "Hypertension and managed care” (managed care supplement article) "Beta-blockers as first-line therapy for hypertension in the elderly” (managed care supplement article) "Cost-Effectiveness of Intensive Treatment of Hypertension” (managed care supplement article) "Angiotensin receptor blockers: how important is selectivity?” (review) "Angiotensin II receptor blockers: evidence for preserving target organs” (review) "Treating hypertension in the elderly” (review) "Ambulatory blood pressure monitoring: dippers compared with non-dippers” (article based on presentation) "Factors affecting circadian variability” (article based on presentation) "Direct renin inhibition: focus on aliskiren” (review) "Clinical trial rationale and design: appropriate blood pressure control in type II diabetes mellitus—Part 2 with valsartan” (clinical trial) Dyslipidemia "Lipid-lowering drug therapy: effectiveness and economics” (review) "Diabetes, insulin resistance, and dyslipidemia” (review) "Recent pharmacologic developments in lipid management” (web editorial) |
Back to Areas of Expertise